Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Saved in:
| Title: | Immune persistence and safety of the AS01 |
|---|---|
| Authors: | Ferguson M; Colchester Research Group, Truro, Canada., Schwarz TF; Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany., Núñez SA; Centro Medico Maffei, Buenos Aires, Argentina., Rodríguez-García J; Preventive Medicine Department, Immunocompromised Patient Immunization Unit, Son Espases University Hospital, University of the Balearic Islands (UIB), Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Mallorca, Balearic Islands, Spain., Mital M; Agnieszka Mital Centrum Badan Klinic, Elblag, Poland., Zala C; Vacunar Sede Las Cañitas, Buenos Aires, Argentina., Pek B; Clinique de Pneumologie et du Sommeil de Lanaudière, Saint-Charles-Borromée, Québec, Canada., Schmitt B; Studienzentrum Mainz Mitte, Mainz, Germany., Toursarkissian N; Praxis Dr. Med. Nicole Toursarkissian, Berlin, Germany., Ochoa Mazarro D; Clinical Pharmacology Department, Hospital Universitario De La Princesa, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain., Großkopf J; Praxis Dr. Med. Josef Großkopf, Wallerfing, Germany., Voors-Pette C; QPS Netherlands B.V, Groningen, The Netherlands., Mehta H; Clinical Research Institute, Minneapolis, MN, USA., Amare Hailemariam H; GSK, Wavre, Belgium., Gérard C; GSK, Rixensart, Belgium., Damaso S; GSK, Wavre, Belgium., David MP; GSK, Wavre, Belgium., Descamps D; GSK, Wavre, Belgium., Hill J; GSK, Wavre, Belgium., Vandermeulen C; GSK, Wavre, Belgium., Hulstrøm V; GSK, Wavre, Belgium. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2579335. Date of Electronic Publication: 2025 Nov 05. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2164-554X |
|---|---|
| DOI: | 10.1080/21645515.2025.2579335 |
